We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.85%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.09B
AUM Growth
+$304M
Cap. Flow
-$377M
Cap. Flow %
-12.21%
Top 10 Hldgs %
47.14%
Holding
153
New
43
Increased
25
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$99.9M
2
ABBV icon
AbbVie
ABBV
+$92.7M
3
LRMR icon
Larimar Therapeutics
LRMR
+$41.5M
4
WBA
Walgreens Boots Alliance
WBA
+$40.8M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$36.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$216M
2
AGN
Allergan Inc
AGN
+$129M
3
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$62.2M
4
NVRO
NEVRO CORP.
NVRO
+$40.5M
5
AERI
Aerie Pharmaceuticals
AERI
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 60.38%
2 Financials 2.52%
3 Technology 0.47%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASPX
1
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$446M 14.45%
4,449,103
+1,500,000
+51% +$99.9M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$332M 10.76%
12,792,689
+1,093,642
+9% +$20M
ABBV icon
3
AbbVie
ABBV
$450B
$89.8M 2.91%
+1,534,000
New +$92.7M
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$87.8M 2.84%
5,073,050
+261,556
+5% +$4.62M
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$87.2M 2.83%
11,834,595
– –
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
$85.8M 2.78%
211,747
+50,280
+31% +$21.3M
BLUE
7
DELISTED
bluebird bio
BLUE
$76.2M 2.47%
48,737
-16,955
-26% -$22.4M
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$73.2M 2.37%
4,072,809
-1,185,666
-23% -$18.6M
DVA icon
9
DaVita
DVA
$15.2B
$59.3M 1.92%
730,000
+295,000
+68% +$22.6M
INFI
10
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$55.5M 1.8%
3,968,155
+110,350
+3% +$1.69M
UAM
11
DELISTED
Universal American Corp
UAM
$55.4M 1.79%
5,186,148
-428,650
-8% -$4.03M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$48.9M 1.58%
+631,192
New +$36.4M
WBA
13
DELISTED
Walgreens Boots Alliance
WBA
$43.4M 1.41%
+512,800
New +$40.8M
LRMR icon
14
Larimar Therapeutics
LRMR
$384M
$41.6M 1.35%
+87,515
New +$41.5M
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$40.3M 1.31%
922,938
+227,564
+33% +$10.6M
GSK icon
16
GSK
GSK
$104B
$40.3M 1.31%
698,548
+247,908
+55% +$14.2M
ELGX
17
DELISTED
Endologix Inc
ELGX
$40.1M 1.3%
234,935
-102,944
-30% -$15.6M
VNDA icon
18
Vanda Pharmaceuticals
VNDA
$327M
$38.4M 1.25%
4,134,157
-5,630
-0.1% -$63.6K
INSM icon
19
Insmed
INSM
$23.5B
$33.9M 1.1%
1,628,531
-613,100
-27% -$10.8M
GWPH
20
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$33.1M 1.07%
+363,700
New +$29.5M
ATRS
21
DELISTED
Antares Pharma, Inc.
ATRS
$32.7M 1.06%
12,078,318
+3,974,000
+49% +$10.1M
EHTH icon
22
eHealth
EHTH
$47.3M
$30.6M 0.99%
3,264,588
+1,000,000
+44% +$11.9M
AET
23
DELISTED
Aetna Inc
AET
$30.3M 0.98%
+284,300
New +$27.9M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$29.9M 0.97%
595,443
+332,818
+127% +$14.3M
XNCR icon
25
Xencor
XNCR
$1.3B
$29M 0.94%
+1,895,535
New +$29.9M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2015 Portfolio in Review

As of Q1 2015, Deerfield Management held 153 positions worth $3.09B, up 11% from $2.78B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deerfield Management withdrew a net $377M in Q1 2015, closing 29 positions and reducing 27 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $216M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AbbVie worth $89.8M.

  • Deerfield Management's largest Q1 2015 buy was AbbVie: 1,534,000 shares worth $89.8M.
  • Deerfield Management added most to AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, an estimated $99.9M increase.
  • Deerfield Management's biggest Q1 2015 reduction was Aerie Pharmaceuticals, cutting an estimated $36.3M.
  • Deerfield Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $216M.
  • Deerfield Management's ten largest holdings make up 47% of its $3.09B portfolio in Q1 2015.
  • Deerfield Management opened 43 new positions and closed 29 in Q1 2015.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $3.09B.

Based on Deerfield Management's 13F filing for Q1 2015, filed 15 May 2015.